We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
On Wednesday, 20 April 2022 EUFOREA will celebrate the launch of the very first Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day in Brussels.
Until now, patients with CRSwNP have had only limited opportunities for their voices to be heard, hence missing the opportunity to contribute to the improvement of CRSwNP care. In 2021, the Patient Advisory Board of EUFOREA published a statement that offered novel insights on the underestimated burden of CRSwNP and shortcomings of current care as well as multiple recommendations for action plans for implementation of better care for CRSwNP among all physicians treating patients with this disabling disease.
The aims of this campaign are:
Mark your calendars, by clicking the below button, for this monumental event and #LetsTalkCRS !
The background of this article focuses on European patients with chronic rhinosinusitis with nasal polyps (CRSwNP) that have had only limited occasions to unite to have their voices heard, hence missing the opportunity to contribute to the improvement of CRSwNP care.
Uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis, as is typically characterized by a type 2 inflammatory reaction and by comorbidities, including asthma, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease and allergies.
© All rights reserved. EUFOREA – European Forum for Research and Education in Allergy and Airway Diseases.